Stockscreener 앱 받기
10.91
0.55%
-0.06
시간 외 거래:
11.02
0.11
+1.01%
전일 마감가:
$10.97
열려 있는:
$11.06
하루 거래량:
856.24K
Relative Volume:
0.79
시가총액:
$551.21M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-2.9566
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
-1.98%
1개월 성능:
-10.43%
6개월 성능:
-20.77%
1년 성능:
+6.23%
1일 변동 폭
$10.86
$11.27
1주일 범위
$10.86
$11.49
52주 변동 폭
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.91 | 554.24M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Will KalVista Pharmaceuticals Inc. stock attract more institutional investorsMarket Trend Summary & Daily Stock Trend Reports - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock reach Wall Street targets2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Price Momentum & Smart Money Movement Tracker - newser.com
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Tips - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.Portfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
Using R and stats models for KalVista Pharmaceuticals Inc. forecasting2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
Will a bounce in KalVista Pharmaceuticals Inc. offer an exit2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockM&A Rumor & AI Driven Price Forecasts - newser.com
Can KalVista Pharmaceuticals Inc. (4XC1) stock sustain margin levelsInsider Buying & Technical Entry and Exit Tips - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock a defensive play amid uncertaintyJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycleJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
How to track smart money flows in KalVista Pharmaceuticals Inc.Weekly Trend Report & Weekly Top Gainers Alerts - newser.com
Emerald Mutual Fund Advisers Trust Increases Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsJuly 2025 EndofMonth & Accurate Entry and Exit Point Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stock2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Emerald Advisers LLC Boosts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving AverageWhat's Next? - MarketBeat
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - The Joplin Globe
KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment? - MSN
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):